Tumor Biology and Microenvironment Program Themes

Theme 1: To identify molecular, cellular determinants of malignancy (metastasis drivers)

Our investigators study key signaling pathways involved in tumorigenicity, tumor cell phenotypical plasticity, and tumor cell drug response (metastasis operatives).

Theme 1 Accomplishments 

Theme 2: To identify and exploit the underlying mechanisms of tumor metastasis (operatives)

Our investigators study the function and underlying mechanisms such as the extracellular proteolysis/signaling network that enable tumor cells to adapt to and eventually overcome the varying microenvironments.

Theme 2 Accomplishments 

Theme 3: To identify and exploit stromal reactivity and host immunity to tumor progression (host response to metastatic tumors)

Our investigators study the interaction of tumor cells with mesenchyme and innate immune cells. We also identify, evaluate and utilize adaptive cellular and humoral immune responses to develop immunotherapy approaches.

Theme 3 Accomplishments 

The Latest From Karmanos Cancer Institute

News

Precision Treatment Wipes Out Prostate Cancer Second Time Around

When Terry Gates started making more frequent trips to the restroom this year, his heart sank. He had been through this before. and he knew exactl...

Read More

Karmanos Cancer Institute Celebrates Survivorship and Strength During National Cancer Survivors Month

The Barbara Ann Karmanos Cancer Institute , cancer centers, and other organizations across the nation recognize June as National Cancer Survivor M...

Read More

IN THE NEWS: Karmanos Cancer Institute Continues Its Community Education Series

WJR Join Karmanos Cancer Institute’s Office of Community Outreach and Engagement (COE) for the second Community Conversations on Cancer series eve...

Read More
News

WJR | Karmanos Cancer Institute Continues Its Community Education Series

Listen Now

WXYT 97.1 The Ticket | ‘Get a Mammogram’

Listen Now

WXYT 97.1 The Ticket | Have Confidence in Who’s Treating You for Cancer

Listen Now